The Intertwined Relationship Between Heart Failure and Atrial Fibrillation, How Can We Untangle It?

과제정보

The author received no financial support for the research, authorship, and/or publication of this article.

참고문헌

1. Park SM, Lee SY, Jung MH, et al. Korean Society of Heart Failure guidelines for the management of heart failure: management of the underlying etiologies and comorbidities of heart failure. Korean Circ J 2023;53:425-51. https://doi.org/10.4070/kcj.2023.0114
2. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Korean Circ J 2023;53:217-38. https://doi.org/10.4070/kcj.2023.0047
3. Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. Korean Circ J 2017;47:644-62.
4. Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One 2021;16:e0244689.
5. Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 2018;25:495-502. https://doi.org/10.1177/2047487318755531
6. Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm 2021;18:1098-105. https://doi.org/10.1016/j.hrthm.2021.03.028
7. Kim M, Ha KH, Lee J, et al. Lower atrial fibrillation risk with sodium-glucose cotransporter 2 inhibitors than with dipeptidyl peptidase-4 inhibitors in individuals with type 2 diabetes: a nationwide cohort study. Korean Circ J 2024;54:256-67.
8. Ling AW, Chan CC, Chen SW, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 2020;19:188.
9. Lee S, Zhou J, Leung KS, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther 2023;37:561-9. https://doi.org/10.1007/s10557-022-07319-x
10. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. Diabetes Obes Metab 2019;21:1136-45. https://doi.org/10.1111/dom.13627
11. Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab 2018;20:344-51. https://doi.org/10.1111/dom.13077